IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Blood 2020 Oct;136(14):1657-1669

Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019003793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530646PMC
October 2020
10.452 Impact Factor

Publication Analysis

Top Keywords

alk inhibition
8
large cell
8
cell lymphoma
8
standard chemotherapy
8
anaplastic large
8
alk inhibitor
8
alk
7
crizotinib alcl
4
upregulation interleukin
4
90% clinical
4
interleukin receptor
4
progressed months
4
clinical trials
4
alcl driven
4
trials subset
4
driven aberrant
4
54% 90%
4
aberrant upregulation
4
subset patients
4
patients progressed
4

Similar Publications